Fig. 2. Integrated analysis of sample collection and genomic alterations at multiple timepoints: schematic and genomic landscape from pre to post-PARPi and autopsy.

a Schematic illustrating the sites of blood and tissue sample collections from multiple timepoints including pre and post-mortem. b Genetic alterations and variant allele frequencies across sample sites, including cfDNA and tissue samples collected pre- and post-PARPi and at time of autopsy. Tumors were subjected to extensive genomic interrogation using MSK-IMPACT. cfDNA was analyzed using either MSK-ACCESS (baseline and progression cfDNA), or WES (autopsy cfDNA). Note, all disease-relevant and oncogenic mutations detected in the MSK-ACCESS, MSK-IMPACT, and WES panels are included above with the exception of mutations seen in cfDNA with variant allele frequencies <1%, as these were considered possible clonal hematopoiesis (pre-PARPi cfDNA: PIK3R1 D464-Y467del, BRCA1 T1485S, post-PARPi cfDNA: TP53 C176Y, TP53 X126_splice).